Dr. Reddy's Laboratories
151 hedge funds and large institutions have $857M invested in Dr. Reddy's Laboratories in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 62 increasing their positions, 40 reducing their positions, and 14 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 40
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
2.2% more ownership
Funds ownership: 46.91% → 49.11% (+2.2%)
2% more funds holding
Funds holding: 148 → 151 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $866M → $857M (-$9.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$14.7M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$9.4M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$5.85M |
| 4 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
+$5.28M |
| 5 |
Morgan Stanley
New York
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$14.1M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$9.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$8.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.13M |
| 5 |
Millennium Management
New York
|
-$2.02M |
RDY Hedge Fund Activity: Q3 2022 in Review
151 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q3 2022, worth a combined $857M — down 1.1% from $866M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RDY positions and 14 closed out — a net gain of 6 holders — while 62 added to existing stakes and 40 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $14.7M. The largest seller was Renaissance Technologies, cutting an estimated $14.1M.
- 151 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q3 2022, up from 148 in Q2 2022.
- Funds reported $857M of Dr. Reddy's Laboratories stock for Q3 2022, down 1.1% quarter-over-quarter.
- 20 funds opened new Dr. Reddy's Laboratories positions in Q3 2022 and 14 closed out, a net change of +6 holders.
- The largest Dr. Reddy's Laboratories buyer in Q3 2022 was Goldman Sachs, an estimated $14.7M added.
- The largest Dr. Reddy's Laboratories seller in Q3 2022 was Renaissance Technologies, an estimated $14.1M sold.
Based on aggregated 13F filings for Q3 2022.